DONG Bang, YOU Xiaoqin, WEN Hongmei, DAI Zhenli, SHAN Chenxiao, WANG Xinzhi, LI Wei. Study on the Excretion of Liguzinediol in Rats by UPLCPDA Method[J]. Journal of Nanjing University of traditional Chinese Medicine, 2016, 32(5): 475-478.
Citation: DONG Bang, YOU Xiaoqin, WEN Hongmei, DAI Zhenli, SHAN Chenxiao, WANG Xinzhi, LI Wei. Study on the Excretion of Liguzinediol in Rats by UPLCPDA Method[J]. Journal of Nanjing University of traditional Chinese Medicine, 2016, 32(5): 475-478.

Study on the Excretion of Liguzinediol in Rats by UPLCPDA Method

More Information
  • Received Date: April 17, 2016
  • Revised Date: August 05, 2016
  • OBJECTIVE To study the excretion of Liguzinediol and its metabolites in rats by UPLCPDA method. METHODS Six SD rats were administered intravenously at a dose of 10 mg/kg. Its urine, bile and feces were collected according to certain time points. The samples were treated by methanol and the supernatant was dried by N2, then dissolved by mobile phase. Liguzinediol and its metabolites in urine, bile and feces were determinated by UPLCPDA. Conversion factor was confirmed through the determination of UV absorption coefficient and molecular weight of prototype drug together with its metabolites. Then the cumulative excretion of Liguzinediol in rats(Dose%) was calculated. RESULTS There were slight differences in the excretion process between female and male rats. The Dose% of Liguzinediol and its main metabolites in female rats urine, bile and feces respectively were 47.94%, 16.67% and 0.648%, and the total Dose% was 65.26%. The Dose% of Liguzinediol and its main metabolites in male rats urine, bile and feces respectively were 35.00%, 20.37% and 1.156%, and the total Dose% was 56.53%. CONCLUSION The UPLCPDA method with the addition of conversion factor can be used to explore the material balance of Liguzinediol in rats, and provide experimental evidence for clinical research.
  • [1]
    刘峥.Liguzinediol先导物的发现及正性肌力活性研究[D].南京:南京中医药大学,2009.
    [2]
    LIU Z. Discovery of lead Liguzinediol and study on the positive inotropic activities[D].Nanjing:Nanjing University of Chinese Medicine,2009.
    [3]
    徐毅,罗卓卡,刘泉明,等.Liguzinediol的正性肌力作用机制及心脏安全性[J].中国药理学与毒理学杂志,2012,26(2):151156.
    [4]
    XU Y, LUO ZK, LIU QM, et al. Positive inotropic mechanism of liguzinediol and heart safety evaluation[J].Chin J Pharmacol Toxicol,2012,26(2):151156.
    [5]
    CHEN L, XU Y, LI W, et al. The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPasedependent mechanism[J].Life Sci,2012,91(1112):402408.
    [6]
    刘峥,卞慧敏,陈龙,等.Liguzinediol对正常大鼠心脏血流动力学的影响[J].中国药学杂志,2009,44(15):11551158.
    [7]
    LIU Z, BIAN HM, CHEN L, et al. Effect of liguzinediol on cardiac hemodynamics in healthy rats[J].Chin Pharm J,2009,44(15):11551158.
    [8]
    张路,李伟,文红梅,等.LCMS/MS测定大鼠血浆中Liguzinediol浓度及药动学[J].中国新药杂志,2013,22(9):10241028,1046.
    [9]
    ZHANG L, LI W, WEN HM, et al. An LCMS/MS method for determining liguzinediol in rat plasma and studying its pharmacokinetics[J].Chin J New Drug,2013,22(9):10241028,1046.
    [10]
    单晨啸.Liguzinediol在大鼠体内的药代动力学研究[D].南京:南京中医药大学,2012.
    [11]
    SHAN CX.Study on the pharmacokinetics and disposition of linguzinediol in rats[D].Nanjing:Nanjing University of Chinese Medicine,2012.
    [12]
    SHAN CX, LI W, WEN HM, et al.Metabolite identification of liguzinediol in dogs by ultraflow liquid chromatography/tandem mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci. 2014,967:6368.

Catalog

    Article Metrics

    Article views (970) PDF downloads (1080) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return